ABSTRACT
Determinar la respuesta inmunológica a la vacunación contra virus de hepatitis B en pacientes pediátricos con enfermedad celíaca. Se revisaron 25 historias clínicas de celíacos diagnosticados entre 2001-2010 por estudios serológico, histopatológicos, genético y esquema de vacunación hepatitis B completo, de los cuales se excluyeron 11 pacientes. Se solicitó anticuerpo contra antígeno de superficie virus hepatitis B. El grupo de celíacos no respondedores fue evaluado posterior a revacunación bajo apego a dieta sin gluten. Se estudiaron 14 pacientes (35,7% hembras, 64,3% varones). 8 pacientes se vacunaron al nacer y 6 después de los 8 años de edad. De los cuales 28,6% tuvieron baja respuesta a la vacunación y 71,4% sin respuesta. La respuesta fue positiva en 3/8 (37,5%) de los pacientes vacunados al nacer y en 1/6 de los mayores de 8 años (16,7%). 4 no respondedores fueron revacunados cumpliendo dieta libre de gluten, evidenciándose respuesta inmunológica positiva en el 75%. Existe una disminución en la respuesta a la vacunación contra hepatitis B en pacientes celíacos, asociado a HLA DQ2 y que la dieta libre de gluten puede mejorar la respuesta inmunológica
To determine the immune response to the vaccination against hepatitis B virus in pediatric patients with celiac disease. Reviewed 25 medical histories of celiac diagnosed between 2001-2010 by serological, histopathological, genetic studies and full hepatitis B vaccination scheme, of which 11 patients were excluded. Also ask antibody against hepatitis B virus surface antigen The group of non-responder celiac was evaluated after revaccination under attachment to diet without gluten. 14 Patients were studied (35.7% females, 64.3% boys). 8 patients vaccinated at birth and 6 after eight years of age. Of which 28.6% had low response to vaccination and 71.4% unanswered. The answer was positive in 3/8 (37.5%) of patients vaccinated at birth and 1/6 of the 8 older (16.7%). not answering. 4 were fulfilling gluten-free diet, showing response immunological positive in 75%. There is a decrease in the response to vaccination against hepatitis B in celiac patients, conditional primarily by HLA DQ2 and that the gluten-free diet can improve the immune response
Subject(s)
Female , Child , Celiac Disease/diagnosis , Celiac Disease/immunology , Celiac Disease/drug therapy , Hepatitis B/immunology , Hepatitis B/drug therapy , Vaccination , Gastroenterology , Pediatrics , Malabsorption Syndromes/complications , Malabsorption Syndromes/diagnosisABSTRACT
Recombinant DNA hepatitis B vaccine (RecomBvax)- produced by VABIOTECH -National Institute of Hygiene and Epidemiology was injected into 319 children from 3 to 6 years old living in 3 communes Thieu Long, Thieu Hung and Thieu Hop of Thieu Hoa district, Thanh Hoa province to evaluate quality of the vaccine in clinical. The results showed that RecomBvax vaccine have high safety and have not significant side effect. The incidence of positive immune response of 3 RecomBvax injections is 91,85% with GMT of 350.6mIU/ml while the protective concentration of antibody needed is 10mIU/ml. RecomBvax is highly safe and immunogenic response equivalent with rHbvax in the control group.
Subject(s)
Hepatitis BABSTRACT
Objective:In order to obtain safer HBV DNA vaccine,recombinant kanamycin resistance eukaryotic expression plasmid containing the gene of HBV surface antigen was constructed and used to study humoral immune response in BALB/c mice.Methods:HBV antigen middle protein(preS2+S) encoding gene fragment was isolated from the recombinant eukaryotic expression plasmid pcDNA-S 2S;subcloned into eukaryotic expression vector pVAX1.After confirmed the presence of the gene by restriction endonuclease analysis,it was used to immunize the healthy BALB/c mice at different doses,and the levels of anti-HBs in serum was determined by ELISA.Results:Restriction endonuclease analysis confirmed recombinant plasmid pVAX-S 2S was what was expected.Serum anti-HBs was detected at the 2nd week after DNA vaccination at all three doses(100 ?g,50 ?g,10 ?g per mice)and their titers were increased with time.Quantitative comparison of the serum anti-HBs levels revealed significant(P
ABSTRACT
Objective:To investigate the feasibility and its action of the therapeutic DNA vaccine for treatment of HBV infection.Methods:By genetic recombinant technique,have constructed 2 eukaryotic expressing plasmids namely pS2.S and pFP,encoding HBV envelope middle protein(preS2+HBsAg) and human leukocyte cytokines fusion protein(IL 2/IFN ?) genes respectively and evaluated its efficacy for inducing cellular immunity in healthy BALB/c mice and HBsAg serum conversion in HBV transgenic(Tg) mice after immunization of the plasmids by intramuscular administration.Results:1.The T cell proliferation by in vitro HBsAg stimulation closely correlated with HBsAg concentration,with its stimulation index(SI=5.6?0.9) in pS2.S immunized group,being significantly higher than that (2.0?0.5) of the control.The IL 2 and IFN ? secretion level in supernatant of the DNA vaccine immunized spleen cell culture were significantly higher than that of the control,while the IL 4 secretion level was not affected.2.The dendritic cells(DCs) extracted from the local draining lymph node(LN) after DNA vaccination induced a HBsAg specific T cell proliferation with its SI(4.20) being higher than that(2.55) of the control.3.In each group of high dose pS2.S and the middle dose combined with pFP inoculation,the HBsAg serum conversion occurred in one HBV Tg mouse,with the serum anti HBs level increasing as the time prolonged,while the serum HBsAg level of the rest mice were significantly lower than that of the control.Conclusion:The results suggest that HBV DNA vaccine can effectively induced cellular immunity in healthy mice;and the preliminary results of the immunized HBV Tg mice may provide an experimental evidence for further investigation of DNA vaccine for its use in treatment of HBV infection.
ABSTRACT
Objective To investigate the effect of therapeutic dual-plasmid HBV DNA vaccine on specific humoral and cellular immunity in cancrivorous monkey (Macaca fascicularis). Methods The eukaryotic expression plasmids encoding human IL-2 and IFN-? fusion protein (pFP) were constructed to enhance the cellular immunity of therapeutic HBV DNA vaccine (pS2.S) encoding HBV envelope middle protein in the form of dual-plasmid (pS2.S+pFP). Thirty cancrivorous monkeys were randomly divided into 5 groups (6 each) with sex rotio of 1∶1, namely the dual-plasmid DNA vaccine group in high dosage (2000?g/kg), medium dosage (660?g/kg), low dosage (200?g/kg), and EP-mediated pFP (330?g/kg) or PBS administration groups as the controls. The monkeys were vaccinated repeatedly with the dual-plasmid HBV DNA vaccine, and then the immune responses including level of serum anti-HBs and number of IFN-? secreting T-cells induced by HBsAg were examined by means of enzyme-linked immunosobent assay (ELISA) and enzyme-linked immunosobent spot assay (ELISPOT) respectively. Results Ten weeks after immunization of HBV DNA vaccine, various levels of serum anti-HBs was detected in all the monkeys of three different dose groups. Sixteen weeks after administration of EP-mediated HBV DNA vaccine, the positive HBsAg-specific INF-? T cell responses was found in 3, 2 and 3 out of 3 monkeys, respectively in the high, medium and low losage groups, and HBsAg-specific INF-? T cell responses were positive in all the animals with the respective cell count of 30.0?13.5 SFCs/3?105 PBMCs, 30.7?26.3 SFCs/3?105 PBMCs and 17.7?6.4 SFCs/3?105 PBMCs in each corresponding group at the 29th week. However, HBsAg-specific INF-? T cell responses were negative in the pFP and PBS group at the same time. Conclusion Electroporation-mediated vaccination of the HBV DNA vaccine can effectively induce both humoral and cellular HBsAg-specific immune responses in cancrivorous monkeys.